publication date: Nov. 30, 2018
Brain cancer immunotherapy SurVaxM extends survival
The latest results from an ongoing clinical study incorporating the immunotherapy SurVaxM as part of combination treatment for glioblastoma show that the investigational drug is safe, well-tolerated and extended survival even among the hardest-to-treat subgroups of patients.
These new findings—including a molecular analysis detailing study participants’ levels of a key biomarker, MGMT—were presented earlier this month at the Society for Neuro-Oncology Annual Meeting in New Orleans.
Robert Fenstermaker and Michael Ciesielski are the co-inventors of SurVaxM, an investigational immunotherapy has shown promise as part of a treatment combination for glioblastoma brain tumors.
With standard glioblastoma therapy—surgery followed by chemotherapy (temozolomide, also known as Temodar), radiation therapy and adjuvant temozolomide—the median overall survival is 15 months.
SurVaxM is a synthetic compound that stimulates the immune system to target a cancer molecule called survivin, a molecule that is highly expressed in glioblastoma and many other cancers.
Sixty-three patients with newly diagnosed glioblastoma were treated with standard of care plus SurVaxM as part of this phase II trial.
The study revealed that:
This treatment combination was well-tolerated. Observed side effects were generally mild, with no regimen-limiting toxicity attributable to SurVaxM
96.7 percent of patients did not experience disease progression within the first six months after initiating this treatment combination.
94.2 percent of study participants were alive one year after their diagnosis, as opposed to 65 percent of patients in a historical comparison group.
The molecular analysis revealed a survival benefit among patients with either form of the MGMT gene, an important marker for prognosis and responsiveness to chemotherapy in patients with glioblastoma.
In this … Continue reading Brain cancer immunotherapy SurVaxM extends survival
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.